Harbor Capital Advisors Inc. Sells 49,302 Shares of Elanco Animal Health Incorporated $ELAN

Harbor Capital Advisors Inc. cut its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 32.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 103,761 shares of the company’s stock after selling 49,302 shares during the period. Harbor Capital Advisors Inc.’s holdings in Elanco Animal Health were worth $2,348,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of ELAN. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new stake in Elanco Animal Health during the 4th quarter valued at $342,000. Brookstone Capital Management bought a new position in Elanco Animal Health during the fourth quarter worth $665,000. Exchange Traded Concepts LLC increased its holdings in shares of Elanco Animal Health by 4.1% in the fourth quarter. Exchange Traded Concepts LLC now owns 273,015 shares of the company’s stock valued at $6,178,000 after purchasing an additional 10,734 shares during the last quarter. First Bank & Trust acquired a new position in shares of Elanco Animal Health in the fourth quarter valued at $223,000. Finally, Legacy Wealth Asset Management LLC bought a new position in shares of Elanco Animal Health in the fourth quarter valued at about $222,000. 97.48% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. KeyCorp increased their price target on shares of Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Barclays started coverage on Elanco Animal Health in a report on Tuesday, December 9th. They set an “overweight” rating and a $30.00 price objective for the company. Leerink Partners increased their target price on Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 24th. UBS Group reissued a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. Finally, JPMorgan Chase & Co. boosted their price target on Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, February 19th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Elanco Animal Health has an average rating of “Moderate Buy” and a consensus target price of $27.67.

Elanco Animal Health Price Performance

Elanco Animal Health stock opened at $23.11 on Friday. The firm has a market cap of $11.49 billion, a PE ratio of -48.14, a price-to-earnings-growth ratio of 2.94 and a beta of 1.88. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.17 and a quick ratio of 1.08. The stock’s fifty day moving average price is $24.56 and its two-hundred day moving average price is $22.82. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $27.72.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The company’s revenue was up 12.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.14 EPS. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, research analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.